Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Abstract
The identification of the antigen recognition receptors for innate immunity, most notably the Toll-like receptors, has sparked great interest in therapeutic manipulation of the innate immune system. Toll-like receptor agonists are being developed for the treatment of cancer, allergies and viral infections, and as adjuvants for potent new vaccines to prevent or treat cancer and infectious diseases. As recognition grows of the role of inappropriate Toll-like receptor stimulation in inflammation and autoimmunity, significant efforts have begun to develop antagonists to Toll-like receptors as well.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TLR antagonists as well as agonists of their negative regulators are now being developed for the treatment of cancer, allergies and viral infections and as vaccine adjuvants to enhance immune responses against tumors and infectious diseases.
“TLR antagonists as well as agonists of their negative regulators are now being developed for the treatment of cancer, allergies and viral infections and as vaccine adjuvants to enhance immune responses against tumors and infectious diseases [44, 45].”
From Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells (2016) · cites this paper as [44]
Cites
Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394 · see citing works
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312 · see citing works
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129 · see citing works
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444 · see citing works
Innate immune recognition of viral infection
Kawai, T., & Akira, S. (2006) · Nature Immunology · doi:10.1038/ni1303 · Cited by 1,899 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
LPS/TLR4 signal transduction pathway
Lu, Y.-C., Yeh, W.-C., & Ohashi, P. S. (2008) · Cytokine · doi:10.1016/j.cyto.2008.01.006 · Cited by 3,301 · see citing works
Vaure, C., & Liu, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00316 · Cited by 842 · see citing works
Sterile inflammation in the liver
Kubes, P., & Mehal, W. Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.008 · Cited by 666 · see citing works
Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits
Brandl, K., Plitas, G., Mihu, C. N., Ubeda, C., Jia, T., Fleisher, M., Schnabl, B., DeMatteo, R. P., & Pamer, E. G. (2008) · Nature · doi:10.1038/nature07250 · Cited by 631 · see citing works
Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9537 · Cited by 588 · see citing works
Self-amplifying RNA vaccines for infectious diseases
Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487 · see citing works
Yu, L.-X., Yan, H.-X., Liu, Q., Yang, W., Wu, H.-P., Dong, W., Tang, L., Lin, Y., He, Y.-Q., Zou, S.-S., et al. (2010) · Hepatology · doi:10.1002/hep.23845 · Cited by 349 · see citing works
The emerging role of Toll-like receptor 4 in myocardial inflammation
Yang, Y., Lv, J., Jiang, S., Ma, Z., Wang, D., Hu, W., Deng, C., Fan, C., Di, S., Sun, Y., et al. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.140 · Cited by 337 · see citing works
Kinnebrew, M. A., Ubeda, C., Zenewicz, L. A., Smith, N., Flavell, R. A., & Pamer, E. G. (2010) · The Journal of Infectious Diseases · doi:10.1086/650203 · Cited by 236 · see citing works
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system
Engel, A. L., Holt, G. E., & Lu, H. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.5 · Cited by 205 · see citing works
Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease
Noelker, C., Morel, L., Lescot, T., Osterloh, A., Alvarez-Fischer, D., Breloer, M., Henze, C., Depboylu, C., Skrzydelski, D., Michel, P. P., et al. (2013) · Scientific Reports · doi:10.1038/srep01393 · Cited by 164 · see citing works
TLR8 signaling enhances tumor immunity by preventing tumor‐induced T‐cell senescence
Ye, J., Ma, C., Hsueh, E. C., Dou, J., Mo, W., Liu, S., Han, B., Huang, Y., Zhang, Y., Varvares, M. A., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201403918 · Cited by 161 · see citing works
Toll-like Receptor 4 and Hepatic Fibrogenesis
Pradere, J.-P., Troeger, J., Dapito, D., Mencin, A., & Schwabe, R. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255353 · Cited by 158 · see citing works
The Toll-like receptor gene family is integrated into human DNA damage and p53 networks
Menendez, D., Shatz, M., Azzam, K., Garantziotis, S., Fessler, M. B., & Resnick, M. A. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001360 · Cited by 148 · see citing works
Pelka, K., Shibata, T., Miyake, K., & Latz, E. (2016) · Immunological Reviews · doi:10.1111/imr.12375 · Cited by 110 · see citing works
RNA Mediated toll-like receptor stimulation in health and disease
Dalpke, A. H., & Helm, M. (2012) · RNA Biology · doi:10.4161/rna.20206 · Cited by 113 · see citing works
Association between toll-like receptors expression and major depressive disorder
Hung, Y.-Y., Kang, H.-Y., Huang, K.-W., & Huang, T.-L. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.07.074 · Cited by 103 · see citing works
Martin, I., Cabán-Hernández, K., Figueroa-Santiago, O., & Espino, A. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401182 · Cited by 95 · see citing works
Toll-like receptors in the respiratory system: Their roles in inflammation
Iwamura, C., & Nakayama, T. (2008) · Current Allergy and Asthma Reports · doi:10.1007/s11882-008-0003-0 · Cited by 76 · see citing works
VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis
Horak, F. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.583237 · Cited by 51 · see citing works
Ramos-Benítez, M. J., Ruiz-Jiménez, C., Aguayo, V., & Espino, A. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-05735-w · Cited by 41 · see citing works
Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells
Menendez, D., Lowe, J. M., Snipe, J., & Resnick, M. A. (2016) · Oncotarget · doi:10.18632/oncotarget.11210 · Cited by 31 · see citing works
- Authors
- Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L.
- Affiliations
- Dynavax Technologies (United States) (US)
- Venue
- Nature Medicine
- Published
- 2007-05
- Volume
- 13
- Issue
- 5
- Pages
- 552-559
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2051940924
- Cited by
- 869
- References
- 5
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 12 · 2023: 29 · 2022: 31 · 2021: 35 · 2020: 33 · 2019: 33 · 2018: 41 · 2017: 36 · 2016: 40 · 2015: 33 · 2014: 64 · 2013: 66 · 2012: 70
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- Toll-like receptors, innate immunity, TLR agonists, cancer immunotherapy, allergy, viral infection, vaccine adjuvants, inflammation, autoimmunity
- MeSH terms
- Animals, Antigens, Humans, Hypersensitivity, Immunity, Innate, Inflammation, Neoplasms, Virus Diseases, Autoimmunity, Models, Immunological, Toll-Like Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
